<DOC>
	<DOCNO>NCT02626455</DOCNO>
	<brief_summary>The purpose study ass whether copanlisib combination standard immunochemotherapy ( rituximab combination bendamustine [ R-B ] rituximab combination 4 drug combination cyclophosphamide , doxorubicin , vincristine prednisone/prednisolone [ R-CHOP ] ) effective safe compare placebo combination standard immunochemotherapy ( R-B R-CHOP ) patient relapse iNHL receive least one , three , line treatment , include rituximab alkylating agent .</brief_summary>
	<brief_title>Study Copanlisib Combination With Standard Immunochemotherapy Relapsed Indolent Non-Hodgkin 's Lymphoma ( iNHL )</brief_title>
	<detailed_description>Patients need fit immunochemotherapy resistant rituximab ( resistance define lack response , progression within 6 month last course treatment rituximab contain regimen ) . This study compose two part : Safety run-in phase III part . The purpose safety run-in part study ass whether drug test ( copanlisib ) combination standard immunochemotherapy ( R-B R-CHOP ) safe dose level study drug ( copanlisib - 45mg 60 mg ) patient able tolerate study treatment combination . In addition find safe tolerable dose level phase III part study , efficacy also evaluate patient stay study treatment safety run-in . The phase III part study start recommend dose copanlisib combination R-CHOP R-B define confirm sponsor , principal investigator Data Monitoring Committee . A maximum 24 patient take part safety run-in part study . In phase III part approximately 676 patient randomly assign blind treatment arm copanlisib plus R-B R-CHOP placebo plus R-B R-CHOP .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>Histologically confirm diagnosis CD20 positive iNHL histological subtype limit : Follicular lymphoma G123a Small lymphocytic lymphoma absolute lymphocyte count &lt; 5x10E9/L study entry Lymphoplasmacytoid lymphoma/Waldenström macroglobulinemia ( LPL/WM ) Marginal zone lymphoma ( splenic , nodal , extranodal ) Patients must relapse least 1 3 prior line therapy , include rituximab alkylating agent . A previous regimen define one following : least 2 month singleagent therapy ; least 2 consecutive cyclesof polychemotherapy ; autologous transplant ; radioimmunotherapy . Previous exposure PI3Ki acceptable provide resistance . NonWM must least one bidimensionally measurable lesion ( previously irradiate ) accord Lugano Classification . Patients affect WM least one bidimensionally measurable lesion baseline radiologic assessment must measurable disease , define presence immunoglobulin M ( IgM ) paraprotein minimum IgM level ≥ 2 x upper limit normal ( ULN ) positive immunofixation test . Male female patient ≥ 18 year age Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 Life expectancy least 3 month Availability fresh tumor tissue and/or archival tumor tissue Screening Adequate baseline laboratory value collect within 7 day start study treatment Left ventricular ejection fraction ( LVEF ) ≥ 50 % Exclusion Criteria Histologically confirm diagnosis follicular lymphoma grade 3b transformed disease , chronic lymphocytic leukemia . Rituximab resistance line therapy ( resistance define lack response , progression within 6 month last course treatment rituximab contain regimen History concurrent condition interstitial lung disease and/or severely impaired lung function ( judged investigator ) Known lymphomatous involvement central nervous system HbA1c &gt; 8.5 % Screening Known history human immunodeficiency virus ( HIV ) infection Hepatitis B ( HBV ) hepatitis C ( HCV ) infection . Patients positive Hepatitis B surface antigen ( HBsAg HBcAb ) eligible negative HBVDNA , patient receive prophylactic antiviral therapy . Patients positive antiHCV antibody eligible negative HCVRNA . Uncontrolled hypertension despite optimal medical management ( per investigator´s assessment ) Congestive heart failure &gt; New York Heart Association ( NYHA ) class 2</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Clinical trial , Phase III</keyword>
	<keyword>Phosphatidylinositol-3-kinase</keyword>
	<keyword>Non-Hodgkin 's lymphoma</keyword>
	<keyword>Indolent B-cell non-Hodgkin 's lymphoma</keyword>
</DOC>